Abstract: px19 is an avian gene recently identified as a bromodexoyuridine (BrdU)-sensitive transcript associated with hematopoiesis in early chick development. Its translation product contains an "LEA" (late embryogenesis abundant) motif which had previously been observed only in plant seed proteins. The present invention provides nucleic acids encoding a human LEA motif protein (HuLEAP) homologous to the avian px19 gene product. Also provided are expression vectors, transformed host cells, and methods of using them to produce recombinant HuLEAP polypeptides.

Abstract: The present invention provides a human pathogenesis-related protein (HPRP) and polynucleotides which identify and encode HPRP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPRP and a method for producing HPRP. The invention also provides for agonists, antibodies, or antagonists specifically binding HPRP, and their use, in the prevention and treatment of diseases associated with expression of HPRP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPRP for the treatment of diseases associated with the expression of HPRP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPRP.

Abstract: The present invention provides a human selenoprotein (HSEL) and polynucleotides which identify and encode HSEL. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HSEL and a method for producing HSEL. The invention also provides for agonists, antibodies, or antagonists specifically binding HSEL, and their use, in the prevention and treatment of diseases associated with expression of HSEL. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HSEL for the treatment of diseases associated with the expression of HSEL. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HSEL.

Abstract: The present invention provides a human proline-rich acidic protein (PRAP) and polynucleotides which identify and encode PRAP. In addition, the invention provides expression vectors and host cells, agonists, antibodies, or antagonists. This invention also provides methods for preventing or treating disorders associated with the expression of PRAP.

Abstract: The present invention provides a novel human chloride channel (HCCP) and polynucleotides which identify and encode HCCP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HCCP and a method for producing HCCP. The invention also provides for agonists, antibodies, or antagonists specifically binding HCCP, and their use, in the prevention and treatment of diseases associated with expression of HCCP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HCCP for the treatment of diseases associated with the expression of HCCP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HCCP.

Abstract: The present invention provides a human mitochondrial membrane protein (HuTIM17) and polynucleotides which identify and encode HuTIM17. The invention also provides expression vectors and host cells and a method for producing HuTIM17. The invention also provides for antibodies or antagonists specifically binding HuTIM17, and their use in the prevention and treatment of cancer. The invention also provides diagnostic assays. The invention also provides for the use of HuTIM17 in identifying antifungal and antiprotozoal therapeutics.

Abstract: The invention provides a human protein phosphatase (PROPHO) and polynucleotides which identify and encode PROPHO. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PROPHO.

Abstract: The present invention provides a human transmembrane protein (ONMO) and polynucleotides which identify and encode ONMO. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing ONMO and for treating or preventing disorders associated with expression of ONMO.

Abstract: The present invention provides a human histone-like protein (HLP) and polynucleotides which identify and encode HLP. In addition, the invention provides expression vectors and host cells, agonists, antibodies, and antagonists. The invention also provides methods for producing HTP and for treating disorders associated with the expression of HLP.

Abstract: The present invention provides a novel human integral membrane (MLF3) and polynucleotides which identify and encode MLF3. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding MLF3 and a method for producing MLF3. The invention also provides for agonists, antibodies, or antagonists specifically binding MLF3, and their use, in the prevention and treatment of diseases associated with expression of MLF3. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding MLF3 for the treatment of diseases associated with the expression of MLF3. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding MLF3.

Abstract: The present invention provides a human apoptosis regulator protein (APRG) and polynucleotides which identify and encode APRG. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding APRG and a method for producing APRG. The invention also provides for agonists, antibodies, or antagonists specifically binding APRG, and their use, in the prevention and treatment of diseases associated with expression of APRG. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding APRG for the treatment of diseases associated with the expression of APRG. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding APRG.

Abstract: The present invention provides a human ubiquitin-conjugating enzyme (UBCPB) and polynucleotides which identify and encode UBCPB. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding UBCPB and a method for producing UBCPB. The invention also provides for agonists, antibodies, or antagonists specifically binding UBCPB, and their use, in the prevention and treatment of diseases associated with expression of UBCPB. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding UBCPB for the treatment of diseases associated with the expression of UBCPB. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding UBCPB.

Abstract: The present invention provides polynucleotides which identify and encode a novel human proteolipid (PLHu). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PLHu. The invention also provides for the use of substantially purified PLHu and its agonists in the commercial production of recombinant proteins for the treatment of diseases associated with the expression of PLHu. Additionally, the invention provides for the use of antisense molecules to PLHu in the treatment of diseases associated with the expression of PLHu. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotides which hybridize with naturally occurring sequences encoding PLHu and antibodies which specifically bind to the protein.

Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human SQM2. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding human SQM2. The invention also provides for the use of purified SQM2 and its agonists in the production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of SQM2. Additionally, the invention provides for the use of SQM2 antagonists and inhibitors, including antisense molecules to SQM2 polynucleotides (i.e., gene sequences) in pharmaceutical compositions for the treatment of diseases associated with the expression of SQM2. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts and/or genomic DNA encoding SQM2 and anti-human SQM2 antibodies which specifically bind to SQM2.

Abstract: The present invention provides polynucleotides which identify and encode novel human proteasome subunit proteins. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding PSUB. The invention also provides for the use of substantially purified PSUB, antagonists, and in pharmaceutical compositions for the treatment of diseases associated with the expression of PSUB. Additionally, the invention provides for the use of antisense molecules to PSUB in pharmaceutical compositions for treatment of diseases associated with the expression of PSUB. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding PSUB or anti-PSUB antibodies which specifically bind to PSUB.

Abstract: The present invention provides a polynucleotide (ubcp) which identifies and encodes a novel ubiquitin-conjugating enzyme (UBCP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding UBCP. The invention also provides for the use of substantially purified UBCP and its agonists, antagonists, or inhibitors in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of UBCP. Additionally, the invention provides for the use of antisense molecules to ubcp in pharmaceutical compositions for treatment of diseases associated with the expression of UBCP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of ubcp or anti-UBCP antibodies which specifically bind to UBCP.

Abstract: The present invention provides a human prostate-associated kallikrein (HPAK) and polynucleotides which identify and encode HPAK. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPAK and a method for producing HPAK. The invention also provides for antibodies or antagonists specifically binding HPAK, and their use, in the prevention and treatment of diseases associated with expression of HPAK. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPAK for the treatment of diseases associated with the expression of HPAK. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPAK.

Abstract: The present invention provides three novel GTP-binding proteins (designated individually as BND-1, BND-2, and BND-3, and collectively as BND) and polynucleotides which identify and encode BND. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding BND and a method for producing BND. The invention also provides for use of BND and agonists, antibodies, or antagonists specifically binding BND, in the prevention and treatment of diseases associated with expression of BND. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding BND for the treatment of diseases associated with the expression of BND. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding BND.

Abstract: The present invention provides a polynucleotide (reg I.gamma.) which identifies and encodes a novel human Reg I.gamma.. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding human Reg I.gamma.. The invention also provides for the use of purified Reg I.gamma. and its agonists in the production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of Reg I.gamma.. Additionally, the invention provides for the use of Reg I.gamma. antagonists and inhibitors, including antisense molecules to reg I.gamma. in pharmaceutical compositions for the treatment of diseases associated with the expression of Reg I.gamma.. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts and/or genomic DNA encoding Reg I.gamma. and anti-human Reg I.gamma. antibodies which specifically bind to Reg I.gamma..

Abstract: The present invention provides two novel human galectins (designated individually as GAL-5HA and GAL-5HB, and collectively as GAL-5H) and polynucleotides which identify and encode GAL-5H. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding GAL-5H and a method for producing GAL-5H. The invention also provides for use of GAL-5H and agonists, antibodies, or antagonists specifically binding GAL-5H, in the prevention and treatment of diseases associated with expression of GAL-5H. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding GAL-5H for the treatment of diseases associated with the expression of GAL-5H. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding GAL-5H.